E

Evotec SE
XETRA:EVT

Watchlist Manager
Evotec SE
XETRA:EVT
Watchlist
Price: 8.41 EUR 0.06% Market Closed
Market Cap: 1.5B EUR
Have any thoughts about
Evotec SE?
Write Note

Net Margin
Evotec SE

-22.1%
Current
-5%
Average
0.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-22.1%
=
Net Income
-171.4m
/
Revenue
777.1m

Net Margin Across Competitors

Country DE
Market Cap 1.5B EUR
Net Margin
-22%
Country US
Market Cap 1.2T USD
Net Margin
9%
Country US
Market Cap 202.3B USD
Net Margin
14%
Country US
Market Cap 166.6B USD
Net Margin
18%
Country KR
Market Cap 66.8T KRW
Net Margin
24%
Country CH
Market Cap 38.4B CHF
Net Margin
9%
Country US
Market Cap 38.8B USD
Net Margin
20%
Country US
Market Cap 36.3B USD
Net Margin
9%
Country US
Market Cap 27B USD
Net Margin
21%
Country US
Market Cap 24.1B USD
Net Margin
17%
Country CN
Market Cap 162.8B CNY
Net Margin
21%
No Stocks Found

Evotec SE
Glance View

Market Cap
1.5B EUR
Industry
Life Sciences Tools & Services

Nestled within Germany's innovation-focused sector, Evotec SE has carved a niche for itself as a leading player in the field of drug discovery and development solutions. From its inception, Evotec has thrived on its commitment to delivering comprehensive solutions that expedite the journey from conceptualization to clinical success. At the core of its business model is a robust and scalable platform approach, which integrates cutting-edge technologies such as high-throughput screening, phenotypic screening, and computational biology. By leveraging these advanced methodologies, Evotec collaborates with pharmaceutical giants, biotech firms, and academic institutions, offering them customized services and shared-risk alliances. This symbiotic partnership model not only accelerates drug discovery but also minimizes the resource constraints typically associated with early-stage research. Evotec's revenue generation is intricately tied to its partnerships and collaborations, which involve milestone and royalty payments, alongside direct service fees. Its business strategy is propelled by a unique combination of proprietary drug development initiatives and strategic collaborative ventures. This dual-pronged approach allows Evotec to share the financial risk of drug development while maintaining potential upside through successful compounds. Moreover, the company's proactive investments in its own pipeline complement the service-based revenue, as they position Evotec to capture significant gains from future licensing or the eventual commercialization of internally researched drugs. With a strong emphasis on scientific excellence and commercial viability, Evotec meticulously balances innovation with strategic foresight, crafting a sustainable business that stands resilient amid the ever-evolving pharmaceutical landscape.

EVT Intrinsic Value
14.13 EUR
Undervaluation 40%
Intrinsic Value
Price
E

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-22.1%
=
Net Income
-171.4m
/
Revenue
777.1m
What is the Net Margin of Evotec SE?

Based on Evotec SE's most recent financial statements, the company has Net Margin of -22.1%.